Research and Markets: Orphan Drugs Partnering Terms and Agreements

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/4j7npr/orphan_drugs) has announced the addition of the "Orphan Drugs Partnering Terms and Agreements" report to their offering.

The Orphan Drugs Partnering Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in orphan drugs partnering deals

- Disclosed headlines, upfronts, milestones and royalties by stage of development

- Orphan drugs partnering contract documents

- Top orphan drugs deals by value

The OrphanDrugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan drugs technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexiblity of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual orphan drugs deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of orphan drugs dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in orphan drugs dealmaking since 2007, including details of disclosed headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading orphan drugs deals since 2007. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC (News - Alert) a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of orphan drugs partnering deals signed and announced since 2007, and where available, a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific oncology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in orphan drugs partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan drugs technologies and products.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in orphan drugs dealmaking

Chapter 3 - Leading Orphan Drugs deals

Chapter 4 - Orphan Drugs dealmaking directory

Chapter 5 -Partnering resource center

For more information visit http://www.researchandmarkets.com/research/4j7npr/orphan_drugs